JP2016507524A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507524A5
JP2016507524A5 JP2015556164A JP2015556164A JP2016507524A5 JP 2016507524 A5 JP2016507524 A5 JP 2016507524A5 JP 2015556164 A JP2015556164 A JP 2015556164A JP 2015556164 A JP2015556164 A JP 2015556164A JP 2016507524 A5 JP2016507524 A5 JP 2016507524A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
pharmaceutical composition
acid residues
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015556164A
Other languages
English (en)
Japanese (ja)
Other versions
JP6363623B2 (ja
JP2016507524A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/014107 external-priority patent/WO2014121053A1/en
Publication of JP2016507524A publication Critical patent/JP2016507524A/ja
Publication of JP2016507524A5 publication Critical patent/JP2016507524A5/ja
Application granted granted Critical
Publication of JP6363623B2 publication Critical patent/JP6363623B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015556164A 2013-01-31 2014-01-31 免疫グロブリンaのレベルを増大するための方法 Active JP6363623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759108P 2013-01-31 2013-01-31
US61/759,108 2013-01-31
PCT/US2014/014107 WO2014121053A1 (en) 2013-01-31 2014-01-31 Methods for increasing immunoglobulin a levels

Publications (3)

Publication Number Publication Date
JP2016507524A JP2016507524A (ja) 2016-03-10
JP2016507524A5 true JP2016507524A5 (https=) 2017-03-09
JP6363623B2 JP6363623B2 (ja) 2018-07-25

Family

ID=50102273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556164A Active JP6363623B2 (ja) 2013-01-31 2014-01-31 免疫グロブリンaのレベルを増大するための方法

Country Status (9)

Country Link
US (1) US9790271B2 (https=)
EP (1) EP2951204B1 (https=)
JP (1) JP6363623B2 (https=)
KR (1) KR102176962B1 (https=)
CN (1) CN105408355A (https=)
AU (1) AU2014212206B2 (https=)
CA (1) CA2899344C (https=)
NZ (1) NZ710744A (https=)
WO (1) WO2014121053A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2647823T3 (es) 2009-05-08 2017-12-26 Vaccinex, Inc. Anticuerpos anti-CD100 y métodos de uso de los mismos
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
BR112014008885B1 (pt) 2011-10-11 2021-02-17 Vaccinex, Inc uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório
NZ629828A (en) 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
MX377858B (es) 2013-06-25 2025-03-11 Vaccinex Inc Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
IL262232B2 (en) 2016-04-22 2024-06-01 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
KR102449406B1 (ko) 2016-08-02 2022-09-29 백시넥스 인코포레이티드 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법
CN112469735B (zh) * 2018-09-18 2022-11-08 天境生物科技(上海)有限公司 用于治疗自发性疾病和癌症的抗cxcl13抗体

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5633149A (en) 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US6692920B1 (en) 1994-12-07 2004-02-17 Incyte Corporation Antibodies to a chemokine expressed in inflamed adenoid
WO1996039522A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
WO1998011226A2 (en) 1996-09-10 1998-03-19 Schering Corporation Mammalian chemokines, related reagents
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
EP1268554A2 (de) 2000-03-31 2003-01-02 IPF Pharmaceuticals GmbH Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion
GB2361003A (en) 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US7052676B2 (en) 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
JP2004517078A (ja) 2000-12-01 2004-06-10 シェーリング コーポレイション 哺乳動物遺伝子および関連試薬の使用
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7919083B2 (en) 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
AU2003294290A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1613657A2 (en) 2003-03-28 2006-01-11 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
CN1842540B (zh) 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
WO2007064911A1 (en) 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
GB0607774D0 (en) 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
WO2007124414A2 (en) 2006-04-21 2007-11-01 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
WO2008121940A1 (en) 2007-03-30 2008-10-09 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
US20110300167A1 (en) 2008-11-04 2011-12-08 Mcmurry Thomas J Cxcr5 receptor compounds
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
US20130310582A1 (en) * 2011-02-04 2013-11-21 Dow Global Technologies Llc Process for removing iron ions from an organic stream
CN104114187A (zh) 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
NZ629828A (en) 2012-03-02 2017-05-26 Vaccinex Inc Methods for the treatment of b cell-mediated inflammatory diseases
BR112015021964A2 (pt) 2013-03-08 2017-08-29 Vaccinex Inc Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos

Similar Documents

Publication Publication Date Title
JP2016507524A5 (https=)
JP2018512138A5 (https=)
JP2022031635A5 (https=)
HRP20181069T1 (hr) Antagonistička protutijela na il-17
JP2020514277A5 (https=)
JP2013506428A5 (https=)
JP2018522888A5 (https=)
JP2020513791A5 (https=)
JP2009225799A5 (https=)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2019054802A5 (https=)
JP2010536384A5 (https=)
JP2016533763A5 (ja) ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物
JP2020508655A5 (https=)
JP2019501883A5 (https=)
JP2020525032A5 (https=)
JP2020055849A5 (https=)
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
JP2017535257A5 (https=)
JP2014511179A5 (https=)
JP2018537421A5 (https=)
JP2017149720A5 (https=)
JP2015163068A5 (https=)
JP2016529882A5 (https=)
JP2014533659A5 (https=)